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ABSTRACT (243 words) 
Barrett’s esophagus (BE) is the only known precursor to esophageal adenocarcinoma.  As 
definitive diagnosis requires costly endoscopic investigation, we sought to develop a risk 
prediction model to aid in deciding which patients with gastroesophageal reflux (GER) 
symptoms to refer for endoscopic screening for BE.  
The study included data from patients with incident nondysplastic BE (n=285) and 
endoscopy control patients with esophageal inflammatory changes without BE 
(“inflammation controls”, n=313).  We used two phases of stepwise backwards logistic 
regression to identify the important predictors for BE in men and women separately: firstly 
including all significant covariates from univariate analyses; then fitting non-significant 
covariates from univariate analyses to identify those effects detectable only after adjusting for 
other factors.  The final model pooled these predictors and was externally validated for 
discrimination and calibration using data from a BE study conducted in western Washington 
State, USA.  
The final risk model included terms for age, sex, smoking status, body mass index, highest 
level of education, and frequency of use of acid suppressant medications (area under the ROC 
curve, 0.70, 95%CI 0.66-0.74).  The model had moderate discrimination in the external 
dataset (area under the ROC curve, 0.61, 95%CI 0.56-0.66).  The model was well calibrated 
(Hosmer-Lemeshow test, p=0.75), with predicted probability and observed risk highly 
correlated.  
The prediction model performed reasonably well and has the potential to be an effective and 
useful clinical tool in selecting patients with GER symptoms to refer for endoscopic 
screening for BE.
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INTRODUCTION 
Esophageal cancer is the sixth leading cause of cancer-related mortality worldwide; in 2008, 
an estimated 482,000 new cases and 407,000 cancer-associated deaths were predicted (1).  In 
the UK, the US and most other Western countries, esophageal adenocarcinoma (EAC) is the 
predominant histological subtype of esophageal cancer (2).  From 1975 to 2001, the rate of 
increase in incidence of EAC was among the highest for any cancer in Western countries, 
with incidence increasing by a factor of 6 in the US (3).  In 2007, the UK reported the 
world’s highest rate of EAC incidence (approximately 5 per 100,000) (4).  Survival for EAC 
is poor as most EAC patients present with metastatic disease and less than 20% survive for 5 
years (5). 
 
Almost all cases of EAC are thought to arise from underlying Barrett’s esophagus (BE), 
progressing through low to high grade dysplasia (6); however the risk of progressing from BE 
to EAC is unclear.  Initial studies suggested that the absolute rate of progression was between 
5 to 10 per 1000 person-years (7), however a recent study in Denmark reported a much lower 
estimate of 1.2 per 1000 person-years (8).  It is widely accepted that gastroesophageal reflux 
(GER) is the principal underlying cause of BE (9), however a number of large population-
based studies have identified other factors associated with BE, including central obesity (10, 
11), and smoking (12).   
 
The identification of patients with BE holds the greatest potential, at least in theory, for 
reducing mortality from EAC.  The challenge remains however, to determine which patients 
presenting with GER symptoms are more likely to have underlying, undiagnosed BE, based 
on their history and symptoms.  Current guidelines from both the British Society of 
Gastroenterology (13) and the American Gastroenterological Association (14) do not 
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recommend endoscopic BE screening of the general GER population.  The American 
Gastroenterological Association do recommend endoscopic BE screening for those with 
multiple risk factors for EAC (including age 50 years or older, male sex, white race, chronic 
GER, hiatal hernia, and elevated body mass index).  However, these guidelines have been 
developed based on expert opinion and weak evidence, and have not been validated (14, 15). 
 
There is growing interest in developing risk prediction models to assist practitioners in 
identifying patients who may benefit most from investigations and interventions.  Models 
have been developed and used for a variety of conditions ranging from cardiovascular 
diseases (16), to cancers of the breast (17-20), lung (21-23), prostate (24), and bladder (25), 
and to melanoma (26).  These models have been shown to be clinically useful and reliable at 
the population level, providing a cost-effective approach to disease prevention and treatment.  
While models have been developed to predict BE in symptomatic patients, they have focused 
on only a restricted list of factors (e.g., age, sex and upper gastrointestinal symptoms) and did 
not consider phenotypic and environmental factors which may explain a high proportion of 
BE cases not attributable to GER (27, 28).  If a comprehensive risk model could be 
developed, it could have the potential to influence clinical decision-making in the care of 
patients with GER.  
 
We aimed to develop and validate a risk prediction model for quantifying the probability of 
BE in patients with frequent GER symptoms and to demonstrate the potential utility of this 
model in the clinical setting for selection of patients for endoscopic screening for the 
presence of BE. 
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MATERIAL AND METHODS 
Study population 
To derive the prediction model, we used data from participants in the Study of Digestive 
Health, a population-based study of BE and reflux-related conditions conducted in Brisbane, 
Australia.  The study population has been described in full previously (12).  We then 
validated the model in a separate case-control study of BE conducted in western Washington 
State, USA (29).   
 
In brief, eligible cases for the Study of Digestive Health were residents of metropolitan 
Brisbane aged 18-79 years with a new (incident) histologically confirmed diagnosis of BE 
(for nondysplastic BE cases) or dysplasia (for dysplastic BE cases) between 1 February 2003 
and 30 June 2006.  BE was defined as the presence of specialized intestinal metaplasia (that 
is, columnar epithelium with goblet cells) in an esophageal biopsy taken from the tubular 
esophagus by upper gastrointestinal endoscopy, irrespective of the length of involvement.  
BE patients were prospectively identified from the private and public pathology laboratories 
servicing metropolitan Brisbane.  Of 1714 patients with presumptive BE, we gained 
permission to contact 1096 (64% response rate).  Of these, 614 were ineligible (487 were 
‘prevalent cases’ with a previous BE diagnosis, 86 had only intestinal metaplasia of the 
gastroesophageal junction, 30 invalid address, 6 too old, 5 other) and 89 were excluded from 
the study (3 too ill, 5 unable to complete an English language questionnaire, 5 unable to be 
contacted, 76 failed to return a completed questionnaire).  Thus, 393 BE cases (285 
nondysplastic, 108 dysplastic) completed the study.   
 
Two separate control groups were recruited for the Study of Digestive Health: ‘inflammation 
controls’ (i.e., patients who underwent endoscopy but for whom the histology report 
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identified only esophageal inflammatory changes consistent with GER and no other 
pathological or macroscopic changes including no evidence of BE), and population controls.  
For the purposes of developing risk prediction models to discriminate patients with BE from 
GERD patients without BE, the present analyses compared the BE cases to the inflammation 
controls only.  In total, 706 of 1354 patients approached as inflammation controls gave 
permission to be contacted (52% response rate).  Of these, 57 refused to participate, 317 were 
ineligible (304 previous diagnosis of inflammation of the esophagus, 11 invalid address, 1 too 
old, 1 other), 19 were excluded (6 uncontactable, 1 psychological problems, 1 too ill, 3 
unable to complete an English language questionnaire, 8 other), and 313 completed the study.   
 
Both cases and inflammation controls were ineligible for the study if they had a previous 
diagnosis of BE or cancer.  Approval to undertake the Study of Digestive was obtained from 
the human research ethics committees of the Queensland Institute of Medical Research and 
all participating hospitals and written informed consent was obtained from all participants. 
 
Candidate predictor variables 
Candidate predictor variables were selected a priori from the literature and practitioner input, 
and included: age (years); highest level of education (school only, technical college/diploma, 
university); body mass index (BMI) 1 year prior to diagnosis (<25, 25-29.9, ≥30 kg/m2); 
smoking status (never smoker, ex-smoker, current smoker); cumulative smoking exposure 
(never smoker, 0-29.9, ≥30 pack-years); smoking duration (never smoker, <15, 15-24, 25-34, 
≥35 years); average lifetime alcohol consumption (non-drinker, <1, 1-6, 7-20, ≥21 
drinks/week); frequency of use of acid suppressant medications (including proton pump 
inhibitors and H2-receptor antagonists) in the past 5 years (never, ever); frequency of use of 
aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) in the past 5 years (never, 
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less than weekly, at least weekly); physical activity levels (low, medium, high); average fruit 
(<2, ≥2 serves/day) and vegetable (<3, ≥3 serves/day) consumption; and number of co-
morbidities (categories defined by Charlson et al. (30)).  A standardized health and lifestyle 
questionnaire was used to collect detailed information on these variables for each participant.  
Most items in the questionnaire showed excellent repeatability after four months (31).  
Furthermore, we conducted a follow-up interview with the BE cases up to seven years after 
diagnosis and found similar self-reports of key characteristics (κ ranged from 0.65 to 0.80), 
suggesting very high reproducibility for these measures.  We imputed data for the small 
proportion of participants with missing values.  We compared the model with imputed data 
with a complete case analysis and found similar model coefficients, but more precise 
estimates with imputed data.        
 
Validation dataset 
The prediction model was externally validated using data from a community-based case-
control study of BE conducted in western Washington State, USA (29).  BE cases were 
defined as residents aged 20-80 years newly diagnosed with BE (i.e., specialized intestinal 
metaplasia in an esophageal biopsy).  Of the 208 patients diagnosed with BE, 193 (92.8%) 
were successfully interviewed.  We subsequently excluded 18 cases who were simultaneously 
diagnosed with esophageal adenocarcinoma (n=2) and/or dysplasia (n=16) from the 
validation analysis.  GERD controls were a random sample of patients (~50%) who 
underwent endoscopy for reflux symptoms, but who were biopsy-proven negative for BE.  Of 
the 463 patients selected to be GERD controls, 418 (90.8%) were successfully interviewed 
and were included in the validation analysis. 
 
Statistical analysis 
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We used basic descriptive statistics to characterize the study populations.  For comparisons 
between BE cases and inflammation controls, we used the χ2 test for categorical variables and 
the Student’s t-test for continuous variables.  Statistical computations were performed using 
SAS software (version 9.2; SAS Institute, Cary, NC), and all tests for statistical significance 
were two-sided at α = 0.05. 
 
Risk model development 
We developed separate risk models to predict nondysplastic BE and dysplastic BE in patients 
with GER symptoms.  However, we were unable to externally validate the results for 
dysplastic BE and report only the nondysplastic BE model here (see supplementary material 
for the dysplastic BE risk model).  As there is a sex difference in the incidence of BE and as 
some risk factors appear to have different associations with BE in men and women, we 
identified the important sex-specific predictors for BE and then pooled these in an overall risk 
model which included a term for sex.  The predictors were identified using two phases of 
stepwise backwards logistic regression.  In the first phase, we included in the multivariate 
model those variables that were statistically significantly associated with BE at the 5% level 
in univariate analyses and we performed a backwards stepwise regression procedure, 
whereby those factors losing their significance in the multivariate analysis were dropped.  In 
the second phase, those factors not significant in the univariate analyses were subsequently 
fitted to the multivariate model to identify those effects detectable only after adjusting for the 
major risk factors.  There was no evidence of multicollinearity between the final list of 
predictor variables (all variance inflation factors << 10) and no interaction terms were 
statistically significant (all p-values for the type III analysis of effects for interaction terms 
were >0.10). 
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Model validation 
The accuracy of the model was assessed using tests for discrimination and calibration (32).  
We evaluated predictive discrimination using the area under the received operator 
characteristic curve (AUC; also known as the c-statistic) and its 95% confidence interval 
(95% CI).  The AUC can be interpreted as the probability that the model will assign a higher 
probability of actually having BE to a randomly chosen patient with BE than to a randomly 
chosen patient without BE, or simply the ability of the model to separate cases and 
inflammation controls.  An AUC of 0.5 indicates that the model has a predictive 
discrimination no better than chance, whereas an AUC of 1.0 indicates a perfectly 
discriminating model.  The second measure calculated was calibration, which compares the 
predicted probability with the observed risk.  When the average predicted risk within decile 
categories matches the proportion observed, the model is well calibrated.  We evaluated 
calibration using the Hosmer-Lemeshow goodness-of-fit statistic (33), where a high p-value 
indicates excellent calibration.  Calibration curves were also plotted to illustrate the model’s 
fit across the range of predicted risk for BE compared with the observed outcome.   
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RESULTS 
Epidemiologic data were available for the derivation analysis from 285 nondysplastic BE 
patients (cases) and 313 inflammation controls (Table 1).  BE cases were more likely to be 
men (64% vs. 47%, p<0.001) and were, on average, 5 years older than inflammation controls.  
The majority (96%-97%) of cases and inflammation controls reported being Caucasian 
(p=0.50). 
 
All the potential predictive covariates with their univariate analyses are presented in Table 2.  
In the univariate analyses among men (181 cases, 147 inflammation controls), highest level 
of education, BMI, tobacco smoking, and frequency of use of acid suppressant medications 
were all statistically significantly associated with BE risk.  In women (104 cases, 166 
inflammation controls), only highest level of education and frequency of use of acid 
suppressant medications were significantly associated with BE risk in the univariate analyses.  
Alcohol consumption, frequency of use of NSAIDs, physical activity, fruit and vegetable 
consumption, and the presence of co-morbidities were not statistically significantly 
associated with BE for men or women in the univariate analyses. 
 
The variables retained in the final multivariate risk model included age, sex, smoking status, 
BMI, highest level of education and frequency of use of acid suppressant medications (Table 
3).  There were no statistically significant interactions between sex and the other variables in 
the final model. 
 
Model performance 
The risk prediction model for nondysplastic BE had good discrimination, with an AUC of 
0.70 (95%CI 0.66-0.74) in the development dataset.  The discriminatory performance of the 
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model in the validation dataset was more moderate with an AUC of 0.61 (95%CI 0.56-0.66).  
Performance of the model was statistically good by the goodness-of-fit test (Hosmer-
Lemeshow test, p=0.75) and the calibration curve (Figure 1) shows good agreement between 
predicted probabilities and actual BE risk across the observed range of risk. 
 
Clinical application using probability thresholds 
To assess the potential effects of using the prediction model to guide referral for endoscopic 
screening for BE, we calculated the proportion of patients that would be referred for 
endoscopy at different probability thresholds for BE (Table 4).  The first row gives the 
scenario of referring every patient with GER symptoms for endoscopy and therefore 
identifying all patients with GER symptoms who have BE (that is, sensitivity is 100%).  If 
patients are referred for endoscopy only if their predicted probability is, for example, 50% or 
more, the proportion of patients referred for endoscopy will be reduced to 46%.  At that 
threshold however, about 41% of BE cases (sensitivity, 59%) will not be referred for 
endoscopy.  As the threshold increases, the number of referrals is reduced; as a consequence, 
however, the number of patients with BE who will not be referred for endoscopy increases. 
 
Cancer Research. 
on June 12, 2013. © 2012 American Association forcancerpreventionresearch.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 11, 2012; DOI: 10.1158/1940-6207.CAPR-12-0010 
13 
 
DISCUSSION 
In this study, we developed and externally validated a clinical risk prediction model for BE 
based on existing data from a large, population-based study.  We used a rigorous statistical 
approach to determine the most important panel of risk factors to predict the presence of BE 
in patients with GER symptoms.  As recent epidemiological studies have shown that some 
risk factors, notably obesity, appear to have different associations with BE in men and 
women, we identified sex-specific predictors and then pooled these in an overall model.  The 
final risk model included terms for age, sex, smoking status, BMI, highest level of education 
and frequency of use of acid suppressant medications.  External validation of the model 
showed that it performed moderately well in discriminating between patients with 
nondysplastic BE complicating their GER (cases) and those with no BE (inflammation 
controls), and the predicted risk correlated well with the observed risk.  
 
As BE is assumed to be an intermediate step in the development of EAC, screening to 
identify people with BE may be an effective strategy to prevent progression to cancer, at least 
in theory.  Given the high prevalence of GER symptoms in the population and low prevalence 
of BE in these patients, endoscopic screening for BE in all patients with GER symptoms is 
not recommended in current international guidelines (13, 14, 34).  The American 
Gastroenterological Association guideline recommends screening in selective populations 
with multiple risk factors for EAC (age 50 years or older, male sex, white race, chronic GER, 
hiatal hernia, and elevated BMI) (14).  The evidence base underpinning these guidelines is 
not strong however, and adherence to the guidelines is likely to be incomplete.  Data for 
Australia are limited, however a New Zealand study showed that approximately 50% of 
indications for endoscopy in 2003 were for heartburn or dyspepsia (i.e., to exclude BE/EAC), 
significantly higher than in 1997 (35).  In healthcare systems throughout the world, there is 
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an increasing need for evidence based strategies including the need to establish an effective 
means of risk stratification for endoscopic BE screening among patients with GER 
symptoms. 
 
Risk prediction can be used in clinical settings to stratify individuals into homogeneous risk 
groups.  Risk prediction models are used in public health to quantify the probability of 
disease based on a combination of risk factors (36).  So far, risk prediction approaches have 
been used extensively for cardiovascular diseases (16), and more recently, there has been a 
focus on deriving cancer risk prediction models (17-26).  These models can complement 
clinical assessment, but they also ensure that the decision making process is more uniform 
across different centers by moving away from using any individual clinician’s personal 
experience (37).   
 
Previous efforts to develop a risk model for BE focused on identifying BE among GER 
patients using gastrointestinal symptoms (27, 28).  While these models performed well 
(AUCs > 0.70), they have not been externally validated.  Our study utilized similar methods 
to derive a risk prediction model for BE using phenotypic and environmental risk factors, and 
tested its performance in an external population.  The variables included in the model are all 
important and not necessarily causal correlates of BE and are supported by published findings 
from our own and other case-control and cohort studies of BE (10, 12, 38-41).  Furthermore, 
to encourage generalizability, we emphasized the use of information on risk factors that can 
be obtained by practitioners in the office setting during routine healthcare.  Importantly, the 
discriminatory accuracy for our model (AUC=0.61 in the external validation dataset) 
compares favorably with cancer risk prediction models, such as the Gail (42) model for 
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Breast cancer risk (0.58) (43), and the LLP (22), Spitz (23), and Bach (21) lung cancer risk 
models (0.69, 0.69, and 0.62, respectively) (44). 
 
Applying this model to all patients with GER symptoms currently being considered for 
endoscopy, and using a threshold for making a decision has the potential to reduce the 
number of unnecessary endoscopies performed to exclude BE.  This model makes explicit the 
proportion of BE cases who would be missed because their predicted risk lies below the 
threshold.  Due to the case-control study design, we were unable to determine precisely the 
positive and negative predictive values for the model.  However, if we assume 5% prevalence 
of BE among persons with GER symptoms, our best estimate is that 5-17% of persons 
referred for endoscopy will have BE (depending upon the cut point chosen for referral) and 
95-100% of persons not referred will not have BE.  Assuming 15% prevalence, 15-41% of 
persons referred for endoscopy will have BE and 85-100% of people not referred will not 
have BE.  In general, determining an acceptable threshold involves a trade-off between 
sensitivity and specificity.  In screening for a lethal cancer for example, high sensitivity is 
desirable, whereas for diseases with lower severity, a lower sensitivity can be tolerated.  For 
our BE model, as the absolute risk of progression to cancer in BE patients is low (8), a 
threshold whereby fewer investigations are performed at the risk of missing more BE cases 
(i.e., increased specificity and decreased sensitivity) may be desirable. 
 
Our study had strengths and limitations.  The large samples of patients newly diagnosed with 
BE in the two settings were recruited prospectively, and comparable, consistent and 
standardized criteria were used for histologic and endoscopic definitions of BE.  Both the 
derivation sample and the validation sample only included patients who were selected for 
endoscopy; the large (but unknown) proportion of patients with GER symptoms not referred 
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for screening had already been triaged away from endoscopy by clinicians using their own 
internal algorithms.  Presumably, the clinicians had decided that those patients were at such 
low risk of significant pathology that there was no net benefit from undergoing endoscopic 
investigation.  As such, it is likely that had those low risk patients been included in the two 
samples, our prediction models would have performed even better.  While our modeling 
assumes that endoscopy is performed in the setting of GER symptoms solely to exclude BE, 
endoscopy may be undertaken for other indications in this clinical setting.  If so, then this 
would tend to attenuate the predictive value of the models we have derived, since those 
patients being referred for other indications would presumably be at lower risk of BE than 
those being referred to confirm the clinical diagnosis.   
 
A limitation of the Australian study was the relatively low rate of participation, raising 
concerns about possible biased selection of cases and controls.  Because BE cases and 
inflammation controls were sampled from the same population, navigated the same clinical 
pathways and were recruited using identical methods, it is unlikely that systematically biased 
selection of one or other group explains our findings.  Moreover, BE cases and inflammation 
controls were not informed about the hypotheses being tested, and so while biased recall of 
non-reflux exposures is possible, we consider the likelihood that this accounts for our 
observations as low.  Although there were 108 dysplastic BE cases in our development 
dataset, we were unable to obtain a validation dataset with dysplastic BE cases.  The best 
estimate for the performance of our model for predicting BE with dysplasia was an AUC 
estimate of 0.87 (95%CI 0.83-0.91) in the development dataset.  Recently, central obesity has 
been found to be more strongly associated with BE than BMI, however measures of central 
obesity (e.g., waist-to-hip ratio) were not collected for this study.  It is likely that adding such 
measures to the model, rather than BMI, may improve predictive accuracy.  Finally, our 
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sample was predominantly white (~97%) and thus the models may not be applicable to other 
ethnic groups.  
 
This parsimonious model however could be considered as a starting point for further 
development, as a number of risk factors were not included and genetic information may also 
be important in predicting risk of BE.  The inclusion of other environmental risk factors and 
the extension of the model to include biomarkers may go further to improving performance.  
However, a recent study has shown that breast cancer risk prediction does not improve 
significantly when genetic information is included in the risk model (45).   
 
In summary, we have derived and externally validated a risk prediction model which 
estimates the likelihood of undiagnosed BE in patients with GER symptoms being considered 
for upper gastrointestinal endoscopy.  The prediction model has the potential to be a useful 
tool in the clinical setting for decisions regarding investigation and treatment of patients with 
GER.
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Table 1. Socio-demographic characteristics of inflammation controls and 
nondysplastic BE cases 
Variables 
Inflammation 
controls (n=313) 
Nondysplastic BE 
cases (n=285) p-valuea 
Mean age (SDb), y 53.5 (12.7) 58.2 (11.9) <.001 
Sex, n (%)    
 Men 147 (47.0) 181 (63.5)  
 Women 166 (53.0) 104 (36.5) <.001 
Ethnicity, n (%)    
 Caucasian 304 (97.1) 274 (96.1)  
 Other 9 (2.9) 11 (3.9) .50 
BE, Barrett’s esophagus. 
ap-value from the two-sided χ2 test (categorical variables) and t-test (continuous variables). 
bSD, standard deviation.
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Table 2. Univariate analyses of nondysplastic Barrett’s esophagus risk factors by sex 
Risk factor 
 Men Women 
 Inflammation 
controls 
 (n=147) 
Nondysplastic 
BE cases 
(n=181) Crude  
OR (95% CI) pa 
Inflammation 
controls 
 (n=166) 
Nondysplastic 
BE cases 
(n=104) Crude  
OR (95% CI) pa  n (%) n (%) n (%) n (%) 
Highest level of education          
 School only  37 (25.2) 68 (37.6) 2.59 (1.37-4.88)  79 (47.6) 70 (67.3) 2.95 (1.31-6.65)  
 Technical college/Diploma  72 (49.0) 86 (47.5) 1.68 (0.94-3.02)  57 (34.3) 25 (24.0) 1.46 (0.61-3.53)  
 University  38 (25.8) 27 (14.9) 1.00 0.01 30 (18.1) 9 (8.7) 1.00 0.006 
Body mass index last year (kg/m2)          
 <25  45 (30.6) 52 (28.7) 1.00  76 (45.8) 36 (34.6) 1.00  
 25-29.9  76 (51.7) 74 (40.9) 0.84 (0.51-1.41)  49 (29.5) 38 (36.5) 1.64 (0.92-2.93)  
 ≥30  26 (17.7) 55 (30.4) 1.83 (0.99-3.38) 0.03 41 (24.7) 30 (28.9) 1.55 (0.84-2.86) 0.19 
Smoking status          
 Never smoker  69 (46.9) 54 (29.8) 1.00  82 (49.4) 44 (42.3) 1.00  
 Ex-smoker  64 (43.5) 95 (52.5) 1.90 (1.18-3.06)  56 (33.7) 42 (40.4) 1.40 (0.81-2.40)  
 Current smoker  14 (9.5) 32 (17.7) 2.92 (1.42-6.01) 0.004 28 (16.9) 18 (17.3) 1.20 (0.60-2.40) 0.48 
Average lifetime alcohol consumption 
(standard drinks/week)b 
         
 Non-drinker  10 (6.8) 14 (7.7) 1.00  22 (13.3) 23 (22.1) 1.00  
 <1  3 (2.0) 9 (5.0) 2.14 (0.46-9.98)  21 (12.6) 13 (12.5) 0.59 (0.24-1.47)  
 1-6  43 (29.3) 45 (24.9) 0.75 (0.30-1.86)  67 (40.4) 49 (47.1) 0.70 (0.35-1.40)  
 7-20  51 (34.7) 56 (30.9) 0.78 (0.32-1.92)  48 (28.9) 17 (16.4) 0.34 (0.15-0.76)  
 ≥21  40 (27.2) 57 (31.5) 1.02 (0.41-2.52) 0.51 8 (4.8) 2 (1.9) 0.24 (0.05-1.25) 0.06 
Frequency of use of acid suppressant 
medications (H2Rs or PPIs) in the past 5 
years 
     
  
  
 Never  102 (69.4) 88 (48.6) 1.00  108 (65.1) 50 (48.1) 1.00  
 Ever  45 (30.6) 93 (51.4) 2.40 (1.52-3.78) <.001 58 (34.9) 54 (51.9) 2.01 (1.22-3.32) 0.006 
Frequency of use of NSAIDS in the past 5 
years 
         
 Never  28 (19.0) 48 (26.5) 1.00  40 (24.1) 25 (24.0) 1.00  
 Less than weekly  87 (59.2) 93 (51.4) 0.62 (0.36-1.08)   88 (53.0) 42 (40.4) 0.76 (0.41-1.42)  
 At least weekly  32 (21.8) 40 (22.1) 0.73 (0.38-1.41) 0.24 38 (22.9) 37 (35.6) 1.56 (0.79-3.06) 0.06 
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Risk factor 
 Men Women 
 Inflammation 
controls 
 (n=147) 
Nondysplastic 
BE cases 
(n=181) Crude  
OR (95% CI) pa 
Inflammation 
controls 
 (n=166) 
Nondysplastic 
BE cases 
(n=104) Crude  
OR (95% CI) pa  n (%) n (%) n (%) n (%) 
Physical activity index          
 Low  35 (23.8) 44 (24.3) 1.13 (0.64-2.01)  54 (32.5) 31 (29.8) 0.96 (0.52-1.78)  
 Medium  57 (38.8) 76 (42.0) 1.20 (0.73-1.98)  55 (33.1) 39 (37.5) 1.19 (0.66-2.15)  
 High  55 (37.4) 61 (33.7) 1.00 0.77 57 (34.3) 34 (32.7) 1.00 0.76 
Average fruit consumption    
 <2 serves/day  67 (45.6) 84 (46.4) 1.00  69 (41.6) 39 (37.5) 1.00  
 ≥2 serves/day  80 (54.4) 97 (53.6) 0.97 (0.63-1.50) 0.88 97 (58.4) 65 (62.5) 1.19 (0.72-1.96) 0.51 
Average vegetable consumption          
 <3 serves/day  83 (56.5) 114 (63.0) 1.00  73 (44.0) 51 (49.0) 1.00  
 ≥3 serves/day  64 (43.5) 67 (37.0) 0.76 (0.49-1.19) 0.23 93 (56.0) 53 (51.0) 0.82 (0.50-1.33) 0.42 
Number of co-morbidities    
 None  33 (22.4) 33 (18.2) 1.00  41 (24.7) 22 (21.1) 1.00  
 ≥1  114 (77.6) 148 (81.8) 1.30 (0.76-2.23) 0.34 125 (75.3) 82 (78.9) 1.22 (0.68-2.20) 0.50 
BE, Barrett’s esophagus; CI, confidence interval; H2R, H2-receptor antagonist; NSAIDs, non-steroidal anti-inflammatory drugs; OR, odds ratio; PPI, proton pump inhibitor. 
ap-value for χ2 test for heterogeneity for comparing group of cases to the inflammation controls for the distribution of each categorical variable. 
bOne standard drink is equivalent to 10g of alcohol. 
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Table 3. Final multivariate logistic model for nondysplastic Barrett’s 
esophagus 
Risk factor 
Adjusteda OR 
(95% CI) 
Age  
 Per 5 years 1.14 (1.06-1.23) 
Sex  
 Women 1.00 (Ref) 
 Men 2.17 (1.50-3.14) 
Smoking status  
 Never smoker 1.00 (Ref) 
 Ex-smoker 1.41 (0.96-2.06) 
 Current smoker 1.93 (1.15-3.24) 
Body mass index last year (kg/m2)  
 < 25 1.00 (Ref) 
 25-29.9 0.96 (0.64-1.44) 
 ≥ 30 1.41 (0.90-2.22) 
Education  
 University 1.00 (Ref) 
 Technical College / Diploma 1.29 (0.77-2.15) 
 School only 2.08 (1.23-3.50) 
Frequency of use of acid suppressant medications 
(H2Rs or PPIs) in the past 5 years 
 
 Never 1.00 (Ref) 
 Ever 2.07 (1.46-2.93) 
AUC (95%CI)  
 Development dataset 0.70 (0.66-0.74) 
 Validation dataset 0.61 (0.56-0.66) 
AUC, area under the receiver operator characteristic curve; CI, confidence 
interval; H2R, H2-receptor antagonist; OR, odds ratio; PPI, proton pump inhibitor. 
aOdds ratios were adjusted for all other terms in the table.
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Table 4. Performance of various probability 
thresholds for referring patients with GER symptoms 
for endoscopy for Barrett’s esophagus 
Probability 
threshold at 
which a 
patient with 
GER is 
referred for 
endoscopy 
Sensitivity 
(%) 
Specificity
(%) 
Patients 
undergoing 
endoscopy 
(%) 
All 100 0 100 
≥0.1 100 0.6 100 
≥0.2 97.5 8.3 94.5 
≥0.3 91.6 28.4 81.1 
≥0.4 75.1 48.9 62.5 
≥0.5 59.3 66.5 45.8 
≥0.6 38.9 80.5 28.8 
≥0.7 17.2 92.7 12.0 
≥0.8 3.9 99.0 2.3 
≥0.9 0 100 0 
GER, gastroesophageal reflux. 
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Figure 1 Logistic calibration curve for validation of model to predict nondysplastic Barrett’s 
esophagus among men and women presenting with gastroesophageal reflux symptoms. 
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